Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403385 · ClinicalTrials.gov registry record · Phase 2
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
A Phase 2 study of Metastatic NSCLC - Non-Small Cell Lung Cancer and Locally Advanced NSCLC - Non-Small Cell Lung Cancer, sponsored by iTeos Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT05403385 is a Phase 2 study of Metastatic NSCLC - Non-Small Cell Lung Cancer and Locally Advanced NSCLC - Non-Small Cell Lung Cancer that is active but no longer recruiting, run by iTeos Therapeutics. The registered enrollment target is 36 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT05403385, a Phase 2 study of Metastatic NSCLC - Non-Small Cell Lung Cancer and Locally Advanced NSCLC - Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by iTeos Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Pemetrexed
- DRUG inupadenant
Study Locations (20)
Other
- Algemeen Ziekenhuis Sint-Lucas - Ghent
- Jessa Ziekenhuis - Hasselt
- AZ Delta - Roeselare
- Vseobecna Fakultni Nemocnice - Prague
- CHU de Caen - Caen
- Hopital de la Timone Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM) - Marseille
- CHU Nantes - Nantes
- Istituto Nazionale dei Tumori - Milan
- Gruppo Humanitas - Istituto Clinico Humanitas - Rozzano
- Centro Oncologico de Galicia - A Coruña
- Hospital Infanta Cristina (Hospital Universitario de Badajoz) - Badajoz
- Hospital Universitario Vall d'Hebron - Barcelona
- Althaia Hospital - Manresa
- Complejo Hospitalario Universitario de Ourense - Ourense
Arkansas
- Highlands Oncology Group - Fayetteville
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Ontario
- William Osler Health System - Brampton
Balearic Islands
- Hospital Universitari Son Espases - Palma de Mallorca
Pamplona
- Complejo Hospitalario de Navarra (CHN) - Pamplona
Valencia
- Hospital Universitari i Politecnic La Fe de Valencia - Valencia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2025-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403385
The ClinicalTrials.gov registry entry for NCT05403385 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is iTeos Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic NSCLC - Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT05403385 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Arkansas, Florida.
Frequently Asked Questions
What is clinical trial NCT05403385 about?
NCT05403385 is a clinical study titled "Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer". The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combina...
What is the current status of trial NCT05403385?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-08-26. Estimated completion is 2025-10.
What conditions does trial NCT05403385 study?
This clinical trial studies the following conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05403385?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Pemetrexed (DRUG), inupadenant (DRUG).
Who is sponsoring clinical trial NCT05403385?
This trial is sponsored by iTeos Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403385 being conducted?
This trial has 20 study locations across Arkansas, Florida, Ontario, Balearic Islands, Pamplona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic NSCLC - Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic NSCLC - Non-Small Cell Lung Cancer
All registered trials for this condition
Locally Advanced NSCLC - Non-Small Cell Lung Cancer
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.